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A fundamental question in advancing Parkinson disease (PD) research is whether it represents one
disorder ormany. Does each genetic PD inform a common pathobiology or represent a unique entity?
Do the similarities between genetic and idiopathic forms of PD outweigh the differences? If aggregates
of α-synuclein in Lewy bodies and Lewy neurites are present in most (α-synucleinopathies), are they
also etiopathogenically significant in each (α-synuclein pathogenesis)? Does it matter that postmortem
studies in PD have demonstrated that mixed protein-aggregate pathology is the rule and pure
α-synucleinopathy the exception? Should we continue to pursue convergent biomarkers that are
representative of the diverse whole of PD or subtype-specific, divergent biomarkers, present in some
but absent inmost? Have clinical trials that failed to demonstrate efficacy of putative disease-modifying
interventions been true failures (shortcomings of the hypotheses, which should be rejected) or false
failures (shortcomings of the trials; hypotheses should be preserved)? Each of these questions reflects
a nosologic struggle between the lumper’s clinicopathologic model that embraces heterogeneity of one
disease and the splitter’s focus on a pathobiology-specific set of diseases. Most important, even if PD is
not a single disorder, can advances in biomarkers and diseasemodification be revised to concentrate on
pathologic commonalities in large, clinically defined populations? Or should our efforts be recon-
structed to focus on smaller subgroups of patients, distinguished by well-defined molecular charac-
teristics, regardless of their phenotypic classification? Will our clinical trial constructs be revised to
target larger and earlier, possibly even prodromal, cohorts?Or should our trials efforts be reconstructed
to target smaller butmolecularly defined presymptomatic or postsymptomatic cohorts? At theKrembil
Knowledge Gaps in Parkinson’s Disease Symposium, the tentative answers to these questions were
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Phenotypic refinements aside, Parkinson disease (PD)
remains largely defined as it was clinically >200 years ago and
pathologically 100 years ago. Technical advances in the ex-
ploration and analysis of pathobiological processes have been
used to validate, rather than to question, this clinicopathologic
construct. As a result, the whole has become the sum of many
and increasing parts. To order the increasing complexity into
an etiopathologic whole, bioinformatic tools integrate mo-
lecular and genetic discoveries, connecting synaptic dysfunc-
tion, failed vesicular trafficking, mitochondrial dysfunction,
impaired proteostasis, α-synuclein (α-syn) pathobiology, and
neuroinflammation as pieces in a single puzzle.1 In the ther-
apeutic realm, promising molecular interventions have been
administered to patients in the absence of relevant measures
of target engagement, that is, bioassays of relevant molecular
pathways rescued by such interventions. Clinical trials aimed
at slowing or halting progressive PD disability are undertaken
with the hypothesis that a molecular modification will affect
common neurodegeneration pathways in most patients with
the clinical diagnosis of PD. Consequently, disease modifi-
cation has remained elusive during the 4 decades in which we
have been trying, with hypotheses and disease constructs
largely unaltered.
The fundamental question is whether PD is one disorder with
varying clinical manifestations influenced by a number of ge-
netic and environmental factors that need to be revised,
thereby allowing current approaches to understanding patho-
genesis and advancing disease modification therapies, or
reconstructed to frame PD as a syndrome in which pathologic
commonalities are subordinate to unique etiologic or patho-
physiologic entities, thereby forcing new approaches to ad-
vancing our understanding of the disease and developing
successful disease modification. Understanding the answer to
this questionwill have far-reaching implications in terms of trial
design, disease modeling, biomarker development, therapeutic
targeting, and so on. A key question is whether the negative
clinical trials of putative disease-modifying interventions have
been true failures (failure of the hypothesis; negative outcomes
deserve to be trusted) or false failures (failure of the trial
methodology; hypotheses deserve another chance).
The Krembil Knowledge Gaps in PD Symposium, held in
Toronto from April 24 to 26, 2019, tackled this fundamental
conceptual challenge: if PD is not a single disorder, can
advances in biomarkers and disease modification be revised to
concentrate on commonalities of pathogenic mechanisms in
large populations (assuming biologic convergence), or do
they need to be reconstructed for application to smaller
subgroups of patients, distinguished by well-defined molec-
ular characteristics, with some mechanistic understanding of
etiopathogenesis and a relevant bioassay to measure it? This
report summarizes the deliberations at that meeting and
acknowledges the unresolved tension between the revisionist
and the reconstructionist approach to PD and its treatment.
Key knowledge gaps in 2019: Revision
or reconstruction?
At the core, the key question is whether PD is one disease with
many facets, each contributing to explaining the whole, or
many diseases sharing some elements with one another but
with distinctive pathogenic elements. As a field, we have lived
with this many-diseases/one-disease tension by reasoning
that both can be correct (figure 1). The road ahead for bio-
marker development and clinical trial efforts toward disease
modification depends on whether PD is a multinodal disease
process connected by α-syn aggregation or a collection of
independent pathologic processes that are largely, if not en-
tirely, independent. The former is the more alluring model:
molecular genetic forms of parkinsonism are considered
pieces of the same puzzle, driving the creation of key research
constructs (table 1).
Knowledge gap 1: Does the heterogeneity of PD
represent a disease spectrum with different
clinical subtypes and rates of progression or
distinct molecular entities, each a separate,
definable disease?
The former premise has been a dominant force. Adopting the
view that PD is a spectrum supports efforts at increasing or
merging ongoing cohorts to maximize scale and deploying
improved analytic processes to the accumulating data (re-
vision). However, the data-driven–generated subtypes thus
far created are not stable over time,2,3 have not been
reproducible,4,5 and do not predict unique patterns of ag-
gregation of α-syn or other pathologies.6,7 Moreover, meas-
urements of putative aggregated protein-based biomarkers
have shown substantial signal overlap between patients and
controls and between disease phenotypes, and replication of
results across cohorts is lacking.8 Combining cohorts an-
chored on clinical criteria and dependent on confirmation of
dopamine deficit is a strategy likely to run into the same
Glossary
AD = Alzheimer disease; α-syn = α-synuclein; CF = cystic fibrosis; CFTR = CF transmembrane conductance regulator;DIAN-
TU = Dominantly Inherited Alzheimer Network Trials Unit; ER = estrogen receptor; GCase = glucocerebrosidase; HER2 =
human epidermal growth factor receptor 2; I-SPY 2 = Investigation of Serial Studies to Predict Your Therapeutic Response
through Imaging and Molecular Analysis 2; IL = interleukin; LRRK2 = leucine-rich repeat kinase 2; PD = Parkinson disease;
SNCA = synuclein; SURE-PD3 = Study of Urate Elevation in Parkinson’s Disease.
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validation and replication difficulties because the problem
may not be one of statistical power but rather of underlying
assumptions. As our biomarker armamentarium broadens,
a reversal of the developmental direction from biomarker to
phenotype, stratifying on the basis of biological clusters of
therapeutic significance rather than on phenotypic classifica-
tion, will require an overhaul of these efforts (reconstruction).
Knowledge gap 2: Will past negative clinical
trials be replaced by future successes if
treatments are delivered to a larger and earlier
cohort or to smaller, biologically defined
populations, prodromal or manifesting?
The conventional view is that failure of clinical trials to meet
efficacy endpoints has 3 primary causes: shortcomings of the
clinical trials themselves (e.g., wrong dosage or insufficient
blood-brain barrier penetration, inadequate target engagement,
insensitive outcome measures, too short a follow-up period),
cohorts too advanced for the intervention of interest to be
effective (once symptoms appear, it may be too late), and poor
translatability from animal models to human trials. Proposals
for revision are aimed at studying larger and earlier cohorts and
creating better animal models. Proposals for reconstruction are
aimed at recruiting more selective cohorts, whether pre-
symptomatic or postsymptomatic, identified by biomarkers
reflecting specific disease mechanisms, ensuring that putative
therapies are tested only in those most likely to respond.
Lessons from other fields
Other fields of medicine have had their share of failures in
biomarker development and clinical trials of disease-modifying
interventions. Did they struggle with moving away from a sin-
gle-disease model? Potentially informative lessons from breast
cancer and the monogenic disease cystic fibrosis (CF) were
discussed at the Krembil Knowledge Gaps Symposium.
Cystic fibrosis
Despite the discovery of the CF transmembrane conductance
regulator (CFTR) gene in 1989, treatments for CF were ex-
clusively symptomatic, targeting the secondary effects of dys-
function in the CFTR protein, involved in the secretion of
chloride and bicarbonate and the regulation of water in the lung,
Table 1 Key research constructs: Differences between revision and reconstruction
Research
construct Support for revision Support for reconstruction
Copathology PD is an α-synucleinopathy; other pathologies must inform
PD variability; α-syn causes or contributes to copathologies
(e.g., seeding)
Mixed pathology is the rule; pureα-syn pathology is the exception;
copathologies are independent and not secondary to α-syn
Resilience Oligomeric species of α-syn are toxic even if they or the
aggregates they become poorly correlate with
neurodegeneration; some regions have greater resistance to
the toxic effects of α-syn
Surviving occurs because of rather than despite α-syn aggregates;
they are absent in certain genetic parkinsonisms and
overexpressed in neurologically normal oldest-old individuals
Prodrome Clinical trials have failed because, once symptoms appear, it
is too late to intervene; earlier is always better
Prodromal PD is also a syndrome: it can evolve into PD, multiple
system atrophy, or dementia with Lewy bodies; earlier is better
only if molecularly subtyped
Phenoconversion Appearance of motor features define PD; cluster of nonmotor
symptoms yields a high risk for meeting threshold for disease
There is no clear biological separation between prodrome and
disease or between nonmotor and motor PD
Abbreviations: α-syn = α-synuclein; PD = Parkinson disease.
Because PD can diagnosed only be when certain motor features are present and its pathology should include only aggregated α-syn, we have wrestled with
PD risk andmodifiers through the constructs of prodrome (any nonmotor features appearing before cardinalmotor features), copathology/mixed pathology
(protein aggregates besides α-syn), resilience (surviving beyond a normal lifespan despite the presence of toxic α-syn in the brain), and phenoconversion (the
moment when motor features meeting current criteria for diagnosis appear in individuals with prediagnostic nonmotor features).
Figure 1 Venn diagrams of the revision vs reconstruction
models for PD
Each numbered circle represents a distinct biological entity or disease. Left,
a model warranting reconstruction. While the diseases are related to one an-
other, they are mostly unique; most biological elements are not shared.
According to thismodel, if α-synuclein (α-syn) is common to all ormost forms of
PD, it cannot be pathogenic to each; genetic Parkinson disease (PD) subtypes
inform about those subtypes and not others. Right, a model best served by
revision. All diseases havemore in commonwith one another; their uniqueness
is mostly theoretical given the large overlap. This model does not discount
a potential important role forα-syn inmany or all of the diseases; a therapy that
mightwork for a genetic PDsubtypemaywork for others. Themodel also allows
the explanation that PDmay involvemultiple pathways, and if we can fix one of
them, we could delay sporadic PD by years.
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sweat glands, pancreas, and gastrointestinal tract. Depending on
whether each of the ≈1,900 CFTR mutations impaired protein
production, its tridimensional functional shape, ion transport
through the channel door, or other aspects of the protein
function, CF was split into 6 major classes. The first disease-
modifying medication, ivacaftor, was found to depend on the
presence of at least 1 G551D CFTR mutation, assayed with
epithelial cells in vitro (not animal models), which excluded 95
of every 100 patients with CF. A promising phase 2 trial (n = 39)
9 of only these genotyped and assay-positive patients was fol-
lowed by a successful phase 3 placebo-controlled trial (n = 84 in
each of 2 arms).10 The first Food and Drug Administration
approval of a disease-modifying intervention for CF occurred 23
years after the discovery of theCF gene. Although it was effective
in only 4% to 5% of patients with CF, it represented a proof of
concept that genetically subtyped diseases could be modifiable
with class-specific therapies. From this small but definite success,
the pool of responders has been increased in selected genetic
and class subtypes with the use of double- and triple-drug
combinations. Critically, the Therapeutic Development Pro-
gram of the Cystic Fibrosis Foundation was instrumental in
derisking pharmaceutical industry high-throughput drug dis-
covery programs and early-phase clinical trials.
Key developmental milestones in CF
The 3 developmental milestones were identification of mu-
tation class-specific response to small molecules, the use of
highly predictive cell-based screening and biomarker plat-
forms that avoided animal models of efficacy, and multidrug
combination of potentiator and corrector therapies with po-
tential for synergism that was evaluated from the outset. The
CF experience provides an example of how even a single-gene
disease was successfully tackled once it was divided into
identifiable molecular subtypes, mechanistically defined with
cell-based biomarkers.
Breast cancer
After a randomized clinical trial in 1981 showed that radical
mastectomy yielded no benefits over quadrantectomy
(breast-preserving surgery),11,12 breast cancer began to be
split into clusters of different pathobiological entities. In-
dividual patient data from randomized trials allowed the
recognition that the benefit of tamoxifen was limited only to
women with estrogen receptor (ER)–positive tumors,
whether premenopausal or postmenopausal.13 Incremental
improvements in survival required the development of other
drug treatments for ER-positive breast cancers, including
aromatase inhibitors, selective ER degraders, CDK4/6
inhibitors, and mammalian target of rapamycin inhibitors.
In parallel, identification of the human epidermal growth
factor receptor 2 (HER2) led to successful clinical trials of
HER2-targeted drug therapies such as trastuzumab (Her-
ceptin), pertuzumab (Perjeta), and trastuzumab-DM1 (Kad-
cyla) in the 20% of women with aggressive HER2-positive
breast cancers,14 but only after post hoc analyses of initially
negative trials revealed the presence of a potential responsive
population. Breast cancer is now divided into several
pathology-molecular subtypes with distinct response to
treatments, relapse patterns, and long-term survival.15
Key developmental milestones in breast cancer
The 3 developmental milestones were recognition of the
molecular basis for disease heterogeneity, subtyping based on
molecular testing and histopathology, and clinical trials with
targeted drug treatments based on molecular subtype. This
experience demonstrates that a single negative trial sufficed to
reject the hypothesis that breast cancer was a single but het-
erogeneous disease.
Conceptual roadblocks in the future
application of these lessons to PD
Should pathology remain the gold standard for
PD diagnosis and biomarker development?
Conceptually, PD is considered an α-synucleinopathy. How-
ever, there is no dose-dependent correlation between Lewy
pathology and cell loss or clinical features. In fact, studies have
found either no16 or negative correlations17 between Braak
stage and cell density in the substantia nigra. Furthermore,
Lewy pathology is not necessary for nigral degeneration, as
demonstrated by the appreciable proportion of leucine-rich
repeat kinase 2 LRRK2- and Parkin-related cases with sub-
stantia nigra neuron loss and motor deficits consistent with
PD but without Lewy bodies.18 Also challenging the primacy
of α-syn pathology, PD is usually associated with abnormal
accumulation of several different types of misfolded proteins;
the exclusive presence of α-syn pathology is the exception, not
the rule.19–21 Lastly, some studies suggest that protein
aggregates may even be compensatory in a brain under mo-
lecular stress and that, with the plausible exception of
α-syn–related genetic PD subtypes (SNCA-PD), α-syn ag-
gregation is neither necessary nor sufficient for neuro-
degeneration or clinical parkinsonism.22
Key roadblocks
Development of biomarkers of diagnostic susceptibility and
detection based on α-syn and other aggregated proteins
may be insufficient for assessing disease trait or state.
Protein aggregates could be related to convergent pro-
tective strategies rather than specific pathogenetic mecha-
nisms.23 Definitive evidence of a direct causal relationship
between Lewy pathology and neurodegeneration in
humans is lacking.
Should pathology be the target of
therapeutic development?
If the extent of the contribution of α-syn aggregation to the
pathogenesis of most subtypes of PD can be questioned, then
targeting it in full length or through specific epitopes of
maximum antigenicity prediction24 may be insufficient or ir-
relevant outside of SNCA-PD. Upregulation of α-syn (and
other inflammatory markers such as Toll-like receptor 2,
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interleukin [IL]-6, and tumor necrosis factor) has been
documented in mice or rats in response to infections or
inflammation.25,26 Within this framework, α-syn aggregation
may behave not unlike an acute-phase reactant, increasing in
concentration during an inflammatory state.
Aggregated β-amyloid has been targeted in Alzheimer disease
(AD) trials over the past 2 decades. Apart from recent in-
triguing but unpublished results suggesting efficacy of adu-
canumab, all 32 phase 2 and 3 antiamyloid clinical trials,
including 6 on prodromal cohorts, have been negative despite
achieving expected target engagement, that is, demonstrating
significant reduction in CSF- or PET-based aggregated
β-amyloid. Critically, nearly 40% of the trials (largely, but not
exclusively, of ɣ secretase and β-secretase inhibitors) have
demonstrated worsening of cognition and, in half of these,
acceleration of hippocampal atrophy in the treated group
compared to placebo. Fourteen clinical trial participants with
pathology-confirmed AD who received β-amyloid42 immu-
nization (AN1792; Elan Pharmaceuticals, Dublin, Ireland)
progressed to moderate or severe dementia despite extensive
plaque removal in all regions examined at postmortem.27
While β-amyloid aggregation and α-syn aggregation are struc-
turally and functionally different targets, 2 main arguments may
predict future failures of targeting α-synwith approaches similar
to those used for β-amyloid: both pathologies often co-occur as
downstream events in sporadic AD and PD; and proteinopathy
burden does not correlate with symptom severity. In sum, these
proteins represent pathologic markers but may not themselves
be pathogenic (etiologic).
Key roadblocks
α-Syn–based biomarkers of disease could have limited value
for the selection of patients for trials of putative disease-
modifying interventions. Targeting α-syn aggregation may
have beneficial effects in selected subsegments of PD (e.g.,
α-syn mutations/multiplications) but could be futile or
harmful in others.
Should distribution of pathology
define progression?
If the presence of α-syn aggregates defines PD, its distribution
has to define PD progression. The autopsy study quantifying
Lewy pathology from individuals with and without PD that
led to the Braak hypothesis was anchored on cases with pa-
thology in the dorsal motor nucleus of the vagus nerve and
accepted a single Lewy neurite as positive for any region.
When considered together, these brains suggested a pattern
with a beginning in the peripheral nervous system, specifically
the Meissner plexa in the gut and in the olfactory bulb, and an
end in the neocortex.28 Although never proved, it has been
assumed that there must be a sequential spread over time
between these distribution patterns, with support from animal
studies showing self-propagation of α-syn from neuron to
neuron through permissive templating in a prion-like
fashion.29,30 Stage 3 of the 6 hypothesized Braak stages of
α-syn progression represents the intersection between the
constructs of prodrome and clinically apparent disease,
according to current motor-centric diagnostic criteria.
The many exceptions to the hypothesis of stereotypical pro-
gression of pathology31 and the fact that symptomatic deficits
align with neuronal degeneration rather than with α-syn ag-
gregation32 render problematic the efforts to calculate disease
progression clinically (e.g., phenoconversion from prodrome to
disease)33 or with longitudinal changes of CSF total α-syn.
Similarly, clinical (e.g., rate of change in Movement Disorders
Society–sponsored Unified Parkinson’s Disease Rating Scale
scores) and imaging (e.g., dopamine transporter striatal bind-
ing ratio signal loss) markers of progression have not detected
meaningful effects on disease progression in trials conducted to
date.Moreover, whatmight define progression on onemeasure
does not on another. Indeed, there is poor concordance of
progression between the Unified Parkinson’s Disease Rating
Scale score and dopamine transporter striatal binding ratios.34
Key roadblock
While convergent dopamine-, clinical-, and α-syn–based bio-
markers may have utility in some populations, biomarkers of
divergence (present in some, absent in most) will be needed
to address the etiologic heterogeneity.
Would testing treatments that failed in early
PD be successful in prodromal PD?
Because earlier treatment is better in many medical con-
ditions, the “too late” argument has often been cited as
explaining past failures in neurodegenerative diseases. If this is
correct, then retesting the interventions of prior trials in
prodromal populations may yield the first success. However, if
PD subsumes many biological subtypes, what is the re-
lationship of prodromal PD to these different subtypes?
In the absence of molecular/biological identification of pro-
dromal disease, we run the risk of extending the negative trials
to prodromal PD, as the AD field has already demonstrated
with antiaggregation interventions in prodromal AD (mild
cognitive impairment). This may be magnified by the fact that
the most common prodromal PD phenotype, REM sleep be-
havior disorder, can also evolve into dementia with Lewy bodies
and multiple system atrophy.35 It is possible that earlier will not
be better if we target a large, clinically defined syndrome rather
than smaller but more homogeneous biological constructs.
Key roadblocks
Molecular criteria for subtyping are needed for both pro-
dromal PD and manifesting PD.
Tying biomarkers to
disease mechanisms
Like the examples of breast cancer and CF, genotype and
molecular subtyping will need to replace phenotypic
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subtyping, which does not predict pathobiology, pathology, or
pathophysiology.6,7 Greater granularity in the clinical char-
acterization of patients, based on more sophisticated semio-
logic, neuroimaging, or wearable technology–based activity
sensors, should be of considerable utility in providing quan-
titative and objective endpoint measures. However, like
“putting the cart before the horse,” these approaches are
unlikely to succeed alone in guiding the development of
biomarkers or selecting patient subtypes for disease-
modifying treatments. These ideas lead to 2 formulations:
c Revision: fitting data to purpose. Genetic risk profiles have
been undertaken with the purpose of enhancing risk
prediction for a disease considered polygenic. Under this
paradigm, the use of multiple common risk alleles can
approach the predictive accuracy of a single gene mutation
in a mendelian disease.36 For instance, rare risk variants in
the glucocerebrosidase (GBA) and leucine-rich repeat
kinase 2 (LRRK2) genes can serve “to distinguish patients
with Parkinson’s disease from healthy controls.”37 Genetic
biomarkers are aimed at enhancing predictive or manifest-
ing (PD/not-PD) diagnostic accuracy in at risk or clinically
defined cohorts, respectively, as well as predicting risk of
progression to key phenotypic outcomes such as de-
mentia.38 Clinical phenotypes act as the independent
variable; genetic and biological measures, the dependent
variable.8 Research on extremes of clinical phenotype (e.g.,
young-onset PD) or genotype (e.g., GBA-PD) inform the
larger whole by providing linked pieces to a disease puzzle
that can be brought into full view through their study.1
c Reconstruction: fitting purpose to data. The exponential
increase in significant hits from genome-wide association
studies (to date, 90 genetic risk loci for PD) may not reflect
contributors to a single phenomenon but expressions of
multiple and mostly independent biological mechanisms,
which may even be conditional on other unmeasured
factors. An examination of these loci as independent
variables might reveal a range of phenotypes, potentially
including but not restricted to the PD spectrum.Under such
a framework, a given GBA mutation explains GBA-PD but
may not meaningfully contribute to the whole of (sporadic)
PD. According to this approach, genetic/biological meas-
ures act as the independent variable; clinical phenotype, the
dependent variable. There is not a single disease puzzle but
several puzzles, each explaining related but molecularly
separate diseases, albeit converging in the selective
vulnerability of specific neuronal populations, most notably
nigrostriatal neurons.
GBA-PD
Similar to CFTR in CF, different GBA mutations lead to dif-
ferent properties of the encoded glucocerebrosidase (GCase)
protein. While some mutations may result in retention of the
protein in the endoplasmic reticulum, other mutations can
affect the interaction with saposin C (GCase activator) in the
lysosome or lead to a complete lack of protein (null muta-
tions).39 Therefore, therapeutic strategies such as chaperones
may be beneficial for only specific mutations, while other
strategies such as gene therapy may conceivably be beneficial
for all mutation carriers. This is further complicated by the fact
that different mutation types (e.g., mild p.N370S or severe
p.L444P) have differential effects on the progression of the
disease.39–41 This differential progression will require strati-
fication by mutation type, even in GBA-specific clinical trials,
to avoid a differential rate of progression in 1 arm of the trial
due merely to different frequencies of specific mutation types
in each group.
Understanding the mechanism for each type of GBA-PD is
likely to allow the identification of GBA-specific biomarkers
and the development of mechanism-specific drugs. Because
a subgroup of patients with sporadic PD have low GCase de-
spite the absence of a GBA mutation,42 recruitment for the
ongoing phase II GBA-specific trial (ClinicalTrials.gov identi-
fier: NCT02906020) includes a subset of patients with sporadic
(non-GBA) PD with low GCase. If the outcome were to be
negative or futile, it would support avoiding further develop-
ments in a wider population than biologically appropriate.
Revision
Although overextending the scope of molecular therapies
compromises their signal-to-noise ratio, studies encompass-
ing >1 GBA mutation (or sporadic PD with low GCase) may
deserve consideration. In reconstruction, subtyping for
mutation-specific GBA-PD will reduce the population avail-
able for recruitment but correspondingly increase the odds of
success (by targeting smaller but better defined subsets).
LRRK2-PD
Certain LRRK2 mutations (e.g., p.G2019S) are associated
with increased LRRK2 kinase activity. Preliminary data sug-
gest that LRRK2 kinase activity may also be increased in some
PD brains without a LRRK2 mutation.43 Thus, a disease-
modifying strategy that aims to inhibit kinase activity is cur-
rently being tested. Cancer has seen successes in applying
a similar strategy with kinase inhibitors (34 kinase inhibitors
were approved by the Food and Drug Administration for
cancer by 2017).44 These successes have, in part, resulted
from applying the concept of kinase dependency in that (1)
kinase inhibitors will be successful only in diseases with
upregulated kinase activity and (2) optimum use of kinase
inhibitors as therapies can be achieved only if coupled with
biomarkers that identify kinase-dependent disease.45 Learning
from these successes in cancer, researchers know that the use
of LRRK2 kinase inhibitors in PD requires development of
diagnostic biomarkers to identify patients with PD with
upregulated LRRK2 kinase activity in the CNS (LRRK2
kinase–dependent PD). Therefore, treatment with LRRK2
kinase inhibitors could potentially be extended to other
patients with PD with enhanced LRRK2 kinase activity
(analogous to patients with PD without GBA mutations but
with evidence of reduced GCase activity). Biomarkers to
measure LRRK2 kinase inhibition in the CNS by these drugs
will also be required. Collectively, these biomarkers will be
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necessary for clinical trials to test the hypothesis that LRRK2
kinase inhibition slows disease progression in patients with
LRRK2 kinase–dependent PD.
Revision without reconstruction
If LRRK2 kinase activity is a pathogenic driver in most
LRRK2-PD and some non–LRRK2-PD, opportunities for
therapies may materialize in >1 genotype and perhaps in
sporadic kinase-dependent PD subtypes.
Inflammation
Markers of immune activation have been observed in most
subtypes of PD. These include peripheral inflammatory
cytokines such as IL-6, tumor necrosis factor, IL-1β, IL-2, IL-
10, and C-reactive protein.46 A more proinflammatory cyto-
kine profile at diagnosis is associated with faster subsequent
motor progression and more cognitive decline.47 However, it
is unclear whether these markers represent downstream
mediators (overlapping areas in the Venn diagram of figure 1)
or upstream etiopathogenic events.
Revision
If causal or contributing, adjunctive anti-inflammatory inter-
ventions may lessen disease progression across most disease
subtypes. Inflammation or immune activation might be par-
ticularly critical at an earlier time than putative interventions
can be enacted and influenced by host factors such as the
microbiome. Alterations in the composition of gut microbiota
have been linked to inflammatory, metabolic, oncologic, and
psychiatric disorders.48 The evidence of aggregated α-syn in
the intestine early in PD, potentially even in normal individ-
uals, makes the gut-brain connection particularly compelling.
In addition, different microbiomes coexist in other body sites
such as the nose, mouth, or the skin, and they too can po-
tentially influence the triggering of PD. The microbiome is
highly dynamic, influenced by host genome variability, region
of residence, age, sex, diet, medications, and PD itself (e.g.,
secondary to constipation).49 Because it is still unclear how
the microbiome might be modulated to affect disease ex-
pression, measuring intestinal microbiota in observational and
interventional studies is imperative to better define its role
across PD subtypes.
Reconstruction
Although epidemiologic evidence suggests that nonsteroidal
anti-inflammatory drugs do not influence PD,50 it remains
possible that subgroups with different patterns of immune
activation could be targeted with selective anti-inflammatory
or immunomodulatory strategies.
Challenges to clinical trials of disease-
modifying drugs: Matching the what
to the who
While many of our explanations for past negative outcomes
have emphasized the “how” (inadequate clinical trials) and
“when” (patients too advanced), if the “what” (right drug,
right target) and “who” (right patients) are perfectly aligned,
the larger anticipated effect size may allow imperfections in
the how (right clinical trial design and execution) and when
(right patient staging).51
Who
Potential therapies known to affect a presumed pathogenic
pathway will require a demonstration that the relevant
mechanism (biomarker of pathogenesis) is active and path-
ogenic in the intended recipients. The selection of study
participants should be based on mechanism rather than
phenotype. As with the experiences in CF and breast cancer,
the first successes may materialize in small populations (likely
<5% of those with PD). The obvious first population to target
will likely be individuals carrying the relatively common risk
factor genes, LRRK2 and GBA.
Stratification
Different treatments are best suited to different subgroups.
Future studies should ideally bank biosamples (blood and
CSF) and cells (e.g., peripheral blood mononuclear cells, in-
duced pluripotent stem cells) to assess for biomarkers of re-
sponse and failure after study participation. Study consent
forms should secure participants’ permission for samples and
data to be used in future analyses after their participation in
the study is completed. This would admittedly represent
a challenge because neuronal cells are more difficult to obtain
than tumor samples (although adult somatic cells could be
reprogrammed into neurons).
Generalizability
GBA- and LRRK2-targeted therapy trials may not generalize
to other forms of PD or, perhaps, to all expressions of GBA
and LRRK2 mutations in manifesting individuals, given that
different GBA and LRRK2 mutations may result in different
pathogenetic mechanisms, as learned from the experience
in CF.
What
As noted above, the what should not be considered in absence
of the who. Of the recent or ongoing phase II/III trials
(inosine, isradipine, deferiprone, and passive α-syn immuni-
zation), only one paired the what with the who most likely to
benefit (inosine for patients with PD with low serum urate
levels in the Study of Urate Elevation in Parkinson’s Disease
[SURE-PD3]). Regardless of how promising a treatment may
have seemed in preclinical studies, it may be possible to
translate that promise to a patient population without etio-
logic enrichment for the targeted pathogenic mechanism and
in a manner that demonstrates target engagement.
From single to multiple therapies
Combined or cocktail treatments will potentially be more
beneficial by targeting >1 dominant pathogenic mechanism in
any given disease subtype.51 However, it is likely that a single
intervention will need to be proven effective in a small patient
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subgroup before the targeted pool can be increased through
the addition of a second intervention (as discussed for CF). In
addition, a combined approach may be best positioned to
address the “triggers, facilitators, and aggravators”52 for each
subtype (e.g., LRRK2-PD), according to any changes in the
relative dominance or contribution of a pathogenic mecha-
nism over time or if several cellular mechanisms act in parallel
rather than in series for that subtype. To add further com-
plexity, defining a therapeutic window for each agent may
require considering a linear relationship between duration of
treatment and side effects but a potentially nonlinear re-
lationship between duration of treatment and efficacy. Finally,
more collaboration to expedite and derisk drug development
by industry will also enhance the ability to study combination
therapies. Precompetitive collaboration (“co-opetition”) is
a business model whereby competitor companies work to-
gether in a competitively safe space to solve problems co-
operatively to the benefit of all.53
How
The traditional approach to clinical trials tends to be costly
and time-consuming, going stepwise from preclinical de-
velopment to clinical phases 1 through 3. An alternative
nimbler and more efficient approach is that of learning and
confirming clinical trials.54 The interest in innovative trial
designs has given rise to adaptive designs, which allow the
review of accumulating information during an ongoing clinical
trial to potentially modify trial characteristics. Challenges to
the application of these concepts to PD, in contrast to selected
other diseases such as breast cancer, include the lower in-
cidence, slow progression, lack of reliable rapid readouts of
changes in underlying disease status, and availability of potent
symptomatic treatments that mask important changes. Tar-
geting patients whose symptomatic management has been
optimized before study entry may mitigate the last issue and
address concerns that any disease-modifying effects may in
part represent (or be masked by) symptomatic benefits.
Adaptive design
Adaptive design actually means adaptive by design. To
properly define the simulations and to preserve the integrity
and validity of the trial, properly designed simulations and
adaptation rules must be specified in advance (planned ad-
aptation) (figure 2). Adaptive enrichment designs represent
a variation that fulfills the desire to target therapies to patients
who can benefit the most from treatment. In such designs,
a trial would initially consider a broad population (e.g., PD
with and without GBA mutations but low GCase). The first
study period, a discovery phase, reveals participant groups
most likely to benefit from treatment (e.g., only patients with
mutation-specific GBA-PD). Participants from this subgroup
are then randomized to treatment groups in a validation
phase. Hence, the study power is increased despite a re-
duction in sample size by focusing only on subgroups most
likely to show benefit. The adaptive design sample size re-
estimation allows adjustment of the sample size based on
a review of the interim data. An internal pilot is a sample size
re-estimation used to reassess nuisance parameters midstudy.
With moderate to large sample sizes, internal pilot designs can
be used to make appropriate modifications with minimal in-
flation of the type I error rate. Thus, there is little reason
(statistically) not to apply this design for most clinical trials.
However, such trial designs are logistically complicated. Strict
attention must be paid to maintaining the blinding and
Figure 2 Planned adaptation allows learning and confirming in adaptive clinical trials
Only planned adaptations can be
guaranteed to avoid unknown biases
resulting from the adaptation (from
Kairalla et al.60). GS = Group sequen-
tial; SSR = Sample-size re-estimation.
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minimizing time gaps during which adaptation decisions are
made to ensure the efficiency and integrity of adaptive studies.
Master protocols
Master protocols are protocols “designed with multiple sub-
studies, which may have different objectives and involve co-
ordinated efforts to evaluate one or more investigational drugs
in one or more disease subtypes within the overall trial
structure,” according to the Food and Drug Administration
Guidance for Industry definition. Master protocols bring ef-
ficiency by creating 1 optimized trial infrastructure applying it
perpetually to study multiple therapies, using the following:
basket trials (test single drug or drug combination in multiple
populations or settings), umbrella trials (test multiple in-
vestigational drugs in a single population), and platform trials
(test multiple therapies in a single disease in a perpetual
manner, with therapies allowed to enter or leave the platform
according to a decision algorithm) (figure 3).
Master protocols use a trial network with shared in-
frastructure to streamline trial logistics, to improve data
quality, and to facilitate data collection and sharing and
a common protocol that incorporates innovative statistical
approaches to study design and data analysis, enabling
a broader set of objectives to be met more efficiently than
would be possible in independent trials. The scientific effi-
ciencies of this type of adaptive design include a shared pla-
cebo group, sample size savings, the study of multiple drugs
and multiple markers, and the flexibility to add/remove
agents. Successful examples in which a platform trial has been
implemented include the Investigation of Serial Studies to
Predict Your Therapeutic Response through Imaging and
Molecular Analysis 2 (I-SPY 2) to screen drugs in neo-
adjuvant breast cancer55 and Dominantly Inherited Alzheimer
Network Trials Unit (DIAN-TU) in at-risk or early-onset
genetic AD.56 The first Platform Trial Initiative for amyo-
trophic lateral sclerosis was recently established at the Healey
Center for ALS at Massachusetts General, with 5 promising
drugs entering evaluation as of September 2019 (massgeneral.
org/neurology/als/research/platform-trial). Public-private
partnership efforts similar to those of the European Pre-
vention of Alzheimer’s Dementia project57 will be required
from the PD community to facilitate the needed application of
these study designs to PD. Efforts from the Critical Path
Institute and the Alzheimer’s Association will also be essential
in cementing the needed collaboration among industry, aca-
demia, and regulatory agencies in developing effective com-
bination therapies for PD, AD, and other neurodegenerative
disorders.58 Challenges in the execution of master protocols
include ensuring the willingness of all sponsors to share data
and matching multiple dosing regimens (frequencies, forms,
and routes) within the trial infrastructure.
Special considerations
There is much to be learned from existing cohorts, including
deep clinical, genetic, and -omics phenotyping, with emphasis
on genetic forms of PD (revision). As argued previously, large
population-based aging cohorts, agnostic to phenotype, will
have the power to find biological signals of pathogenic
mechanisms for which putative therapies already exist and
could be repurposed. Proof-of-concept adaptive clinical trials
of putative disease-modifying drugs can be embedded within
biomarker-development cohorts (reconstruction).
Financial risk/hypothesis certainty
While the mechanism adopted by the CF research community
was instrumental in derisking pharmaceutical industry drug
discovery and early-phase clinical trials, particularly to manage
failures due to safety, drugs can fail on efficacy. Thus, it is
imperative to have high confidence in the therapeutic hy-
pothesis being tested in a clinical trial and the likelihood of
adequate target engagement. No derisking effort can prevent
candidate drugs from failing on efficacy because patients were
not selected on the basis of the mechanism of action that the
potential drug is purported to have. The complex interplay
between the financial risks and the certainty of the therapeutic
hypothesis has been elegantly addressed for rare diseases.59 If
the fundamentals about drug development for disease modi-
fication were to move from a large indication (e.g., sporadic
PD), for which a high risk tolerance is mitigated by the po-
tential of future astronomical returns even with very low
probability of success (revision), to a small indication (e.g.,
a molecular PD subtype; reconstruction), the development
process would tolerate less risk, and the therapeutic hypoth-
esis would have to be definitive rather than tentative. A rare-
disease model would also need to rely on orphan designation
for cost and revenue advantages and exploit the potential of
drug repurposing.
Animal models in drug development
Animal models cannot be expected to recapitulate the com-
plexity of a human disease that exists in many forms and
typically presents late in life. Although some fields (e.g., CF)
have abandoned the reliance of therapeutic development on
animal models, they could serve to understand specific
mechanisms suggested by biospecimens and neuroimaging
Figure 3 Platform trial example
It allowsmultiple drugs examined from the outset, which can be removed or
combined (e.g., A + C). It also permits new drugs (D) to be examined at a later
time point in the same trial.
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studies in humans (revision). The need for research applica-
tions to demonstrate efficacy first in animal models before
prospective trials can proceed in humans will need to be
reconsidered (reconstruction).
Conclusions
As recently articulated,51 more critical than the tools of
warfare (clinical trial designs, endpoint sensitivity, treat-
ments themselves) may be the reconfiguration of warfare
itself. The who/what we are fighting for has not evolved
from the days of blunt targeting of early PD, in which so-
phisticated weapons were deployed on a population with-
out evidence of vulnerability to the effect of those weapons.
Some aspects of our approach can benefit from a revision
strategy, an immediate evolutionary adaptation, or short-
cut. Many areas require reconstruction, which needs not
take longer but may be more revolutionary than evolu-
tionary and will certainly be disruptive. The tension be-
tween revision and reconstruction may not be solved in the
short term (table 2).
Revision (shortcut)
Opportunities exist for harnessing existent and accruing
genetic cohorts, most meaningfully in GBA-specific clinical
trials for GBA-PD subtypes stratified by mutation type and
in kinase-dependent PD subtypes selected through bio-
markers of upregulated kinase activity for targeting with
kinase inhibitors. If LRRK2 kinase activity is a pathogenic
driver in non–LRRK2 kinase-dependent PD, treatment
success may materialize in >1 kinase-dependent PD
genotype/subtype. In addition, ongoing and future clinical
trials in genetic and even nongenetic cohorts can gather
data to generate markers of response and failure to refine
the “who” in subsequent efforts.
Table 2 Point-counterpoint: Revision vs reconstruction
Revision Reconstruction
About the lessons from other diseases (e.g., cystic fibrosis and breast cancer)
Many treatments were developed without subtyping (e.g.,
bisphosphonates for osteoporosis, antibiotics for peptic ulcers).
Other diseases achieved first successes once divided into biomarker-
driven subgroups (e.g., calcium, Helicobacter pylori).
About clinical subtypes
Data-driven clinical subtyping can be used to explain differences in
clinical course and may eventually predict biological subtyping.
Clinical data-driven subtypes are not stable or reproducible between
studies4,5 or are related to unique pathologies.
About pathology as axis of disease
α-Syn aggregation is so common that it must be a key to pathogenesis.
The reason for poor correlation with cell loss is that cells are dead, so
no α-syn is left. Other species of α-syn (i.e., nonaggregated oligomers)
may be of greater importance.
α-Syn aggregation is neither necessary nor sufficient for cell loss to occur
or for clinical parkinsonism. α-Syn aggregation has never been proven to
lead to degeneration or to correlate with symptoms.
Whereas tau pathology might bemore important than β-amyloid in AD,
there is no support for a second pathology in PD; thus, the parallels
are unjustified. The role of copathologies is uncertain and could be
secondary to α-syn (e.g., seeding).
Pure α-syn aggregation has been shown to be the exception, not the rule
(80% copathologies in PD; see also table 1). β-Amyloid and tau co-occur
with α-syn in 8/10 pathology-proven cases of PD.
About pathology as target for therapy
If the wrong species of α-syn is targeted, a negative trial would notmean
that α-syn is irrelevant to PD. α-Syn is important for PD even if
aggregation may not be the appropriate target.
All α-syn species are present across all PD subtypes; a single species
cannot be pathogenic in all. α-Syn antiaggregation drugs might be of
benefit in SNCA-PD but futile in other subtypes.
About clinical trials of disease-modifying interventions
Until trials prove adequate brain penetration and target engagement,
hypotheses are not invalidated. Failure of antiamyloid drugs in AD
does not predict failure of targeting α-syn in PD.
Refinements in trial design and execution suggest that negative trials are
a problem with the hypotheses. Despite target engagement, the
antiamyloid approach has yielded 33 null trials.
If the cohort is too selective, recruitment becomes impossible and will
fail to detect even moderate benefit. Negative tests of any pathway
biomarker may not exclude a possible contributing role of this
pathway, and potential benefit would be missed for those lacking the
biomarker of interest.
Targeted recruitment to those with biomarkers of disease/target
engagement will predict large effect sizes and small sample sizes; large
early/prodromal cohorts without biomarkerswill be unlikely to respond to
mechanistic treatments.
Mechanism of action for drugs is often unknown; target engagement is
unmeasurable; andCSF changes are not equal to brain changes. In the
absence of highly predictive biomarkers, it is reasonable to target
broadly common mechanisms, including the toxic effects of α-syn or
inflammation.
It is imperative to be certain about the therapeutic hypothesis being tested
and the likelihood of adequate target engagement. If PD is many diseases
and α-syn and inflammation are common to most, they are unlikely to be
pathogenic in all.
Abbreviations: AD = Alzheimer disease; α-syn = α-synuclein; PD = Parkinson disease; SNCA = synuclein gene.
10 Neurology | Volume 94, Number 11 | March 17, 2020 Neurology.org/N
Copyright © 2020 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Reconstruction (long-cut)
While drug combinations are a future expectation, proving
success of individual drugs will require ascertainment of
molecular PD subtypes regardless of progress in clinical trial
designs. The ongoing phenotype-based biomarker de-
velopment programs will need to evolve into phenotype-
agnostic biology-driven biomarkers, able to distinguish caus-
ative mechanisms from nonspecific, late, or common/
convergent mechanisms, inappropriate or inadequate as
therapeutic targets. The therapeutic paradigm for neuro-
protection will have to emulate the lessons from other fields of
medicine, tailoring biology-specific/multimechanism strate-
gies to well-defined PD subtypes. Although there will be value
in post hoc responder analyses of future large clinical trials, the
more biologically enriched the targeted groups for the treat-
ment of interest are, the greater the odds of therapeutic
success.
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